Neumora Therapeutics, Inc. (NMRA)
NASDAQ: NMRA · Real-Time Price · USD
9.69
-0.10 (-1.02%)
Nov 21, 2024, 4:00 PM EST - Market closed
Neumora Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
124
Market Cap
1.57B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | - | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Clover Health Investments | 2.12B |
GoodRx Holdings | 790.39M |
10x Genomics | 629.74M |
Certara | 372.80M |
Immunocore Holdings | 296.31M |
Dynavax Technologies | 260.81M |
Arvinas | 161.10M |
Xencor | 85.16M |
NMRA News
- 8 days ago - This biotech's stock could double if its treatment for major depressive disorder succeeds, says Mizuho - Market Watch
- 9 days ago - Neumora Therapeutics, Inc. (NMRA) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 9 days ago - Neumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 15 days ago - Neumora Therapeutics to Participate in Upcoming Conferences in November - GlobeNewsWire
- 3 months ago - Neumora Therapeutics to Host Key Opinion Leader Roundtable to Discuss the Potential of Navacaprant in Neuropsychiatric Disorders - GlobeNewsWire
- 5 months ago - Neumora Therapeutics Announces Initiation of Phase 1b Study of NMRA-511 for Treatment of Alzheimer's Disease Agitation - GlobeNewsWire
- 6 months ago - Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression - GlobeNewsWire
- 7 months ago - Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire